NCT07684612 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07684612
Title	A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Acronym	BEHOLD-Ovarian02
Recruitment	Recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	GlaxoSmithKline
Indications	fallopian tube carcinosarcoma ovary transitional cell carcinoma ovary serous adenocarcinoma peritoneal serous adenocarcinoma endometrioid ovary carcinoma ovarian carcinosarcoma ovary epithelial cancer fallopian tube transitional cell carcinoma fallopian tube serous adenocarcinoma peritoneum cancer fallopian tube cancer
Therapies	Bevacizumab + Mocertatug rezetecan Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin Bevacizumab Bevacizumab + Carboplatin + Gemcitabine
Age Groups:	adult \| senior
Covered Countries	CAN \| AUS

Facility	Status	City	State	Zip	Country	Details
GSK Investigational Site	RECRUITING	Newcastle	New South Wales	2298	Australia	Details
GSK Investigational Site	RECRUITING	Toronto	Ontario	M5G 1Z5	Canada	Details
GSK Investigational Site	RECRUITING	Montreal	Quebec	H4A 3J1	Canada	Details
GSK Investigational Site	RECRUITING	Hokkaido		003-0804	Japan	Details
GSK Investigational Site	RECRUITING	Hyōgo		673-8558	Japan	Details
GSK Investigational Site	RECRUITING	Ibaraki		305-8576	Japan	Details
GSK Investigational Site	RECRUITING	Seoul		03722	South Korea	Details
GSK Investigational Site	RECRUITING	Seoul		135-710	South Korea	Details
GSK Investigational Site	RECRUITING	Seoul		138-736	South Korea	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07684612Clinical Trial Detail